Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Update

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) was the recipient of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 26,900 shares, a drop of 25.9% from the November 30th total of 36,300 shares. Approximately 0.1% of the company's shares are short sold. Based on an average daily volume of 119,300 shares, the short-interest ratio is currently 0.2 days.

Institutional Investors Weigh In On Xtant Medical

A hedge fund recently raised its stake in Xtant Medical stock. Geode Capital Management LLC grew its holdings in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 70.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 515,006 shares of the medical device company's stock after purchasing an additional 212,394 shares during the period. Geode Capital Management LLC owned approximately 0.37% of Xtant Medical worth $348,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 69.33% of the company's stock.

Analyst Ratings Changes

Separately, Craig Hallum set a $1.50 price target on shares of Xtant Medical and gave the stock a "buy" rating in a research report on Friday, October 18th.

Xtant Medical Stock Up 6.9 %

Shares of Xtant Medical stock traded up $0.03 on Friday, hitting $0.46. The stock had a trading volume of 75,904 shares, compared to its average volume of 113,672. The company has a market capitalization of $64.51 million, a P/E ratio of -3.57 and a beta of 0.34. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.88 and a current ratio of 2.12. Xtant Medical has a 52-week low of $0.33 and a 52-week high of $1.31.

Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) last announced its earnings results on Tuesday, November 12th. The medical device company reported ($0.04) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). The business had revenue of $27.94 million during the quarter. Xtant Medical had a negative net margin of 15.45% and a negative return on equity of 37.07%.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.